Edgar Filing: BELLICUM PHARMACEUTICALS, INC - Form 4

BELLICUN Form 4 June 19, 20	M PHARMACEU	TICALS,	INC							
FORN Check to if no los subject Section Form 4 Form 5 obligati may cos See Inst 1(b).	S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Sectio of the Investment Company Act of 1940				N OMB Number: Expires: Estimated burden hou response	irs per				
1. Name and Address of Reporting Person <u>*</u> McGuyer Frank B.			2. Issuer Name and Ticker or Trading Symbol BELLICUM PHARMACEUTICALS, INC [BLCM]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_ Director 10% Owner				
(3. Date of Earliest Transaction(Month/Day/Year)06/17/2015			Officer (give title Content of the officer (specify below)			
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Tat	ole I - Non-l	Derivative	Securities	Acquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemo Execution any (Month/Da	ed Date, if	3.	4. Securit nAcquired Disposed (Instr. 3, 4	ies (A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Reminder: Re	eport on a separate line	e for each cl	ass of sec	urities bene	Perso inform requir	ns who re nation cor red to resp	or indirectly. espond to the colle ntained in this form oond unless the fo ently valid OMB co	are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)				7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 E S (1
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 22.63	06/17/2015		А	10,000	<u>(1)</u>	06/16/2025	Common Stock	10,000	

Edgar Filing: BELLICUM PHARMACEUTICALS, INC - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships					
		Director	10% Owner	Officer	Other		
McGuyer Frank B. C/O BELLICUM PHARMACEUTI 2130 W. HOLCOMBE BLVD., STI HOUSTON, TX 77030		X					
Signatures							
/s/ Ken Moseley, Attorney-in-Fact	06/19/2015						
**Signature of Reporting Person	Date						

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option vests in twelve equal monthly installments following the grant date such that the option will be fully vested on the day immediately preceding the next annual meeting of stockholders of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.